-+ 0.00%
-+ 0.00%
-+ 0.00%
Hanyu Pharmaceutical announced that the company recently received the “Drug Clinical Trial Approval Notice” for HY3003 injections approved and issued by the State Drug Administration, agreeing to carry out clinical trials of this product for adult weight management indications. HY3003 is a novel GLP-1R/GIPR/GCGR triple receptor agonist deployed by the company. The approved injection is administered subcutaneously once a week. At present, global research and development of the project is progressing smoothly. HY3003 injection has obtained clinical trial approval from the US FDA and overseas clinical development is being promoted; the company has submitted a drug clinical trial application for HY3003 tablets to the State Drug Administration and has been accepted.
Share
Listen to the news
Hanyu Pharmaceutical announced that the company recently received the “Drug Clinical Trial Approval Notice” for HY3003 injections approved and issued by the State Drug Administration, agreeing to carry out clinical trials of this product for adult weight management indications. HY3003 is a novel GLP-1R/GIPR/GCGR triple receptor agonist deployed by the company. The approved injection is administered subcutaneously once a week. At present, global research and development of the project is progressing smoothly. HY3003 injection has obtained clinical trial approval from the US FDA and overseas clinical development is being promoted; the company has submitted a drug clinical trial application for HY3003 tablets to the State Drug Administration and has been accepted.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending